Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women

American Journal of Therapeutics
J I SchwartzJohn A Wagner

Abstract

Laropiprant is a prostaglandin D2 receptor 1 antagonist that is being developed in combination with niacin for the treatment of dyslipidemia. This randomized clinical study evaluated the effect of laropiprant on the pharmacokinetics of ethinyl estradiol (EE) and norelgestromin (NGMN), the principal circulating metabolite of norgestimate, in healthy women receiving 3 or more months of an oral contraceptive (Ortho Tri-Cyclen; Ortho-McNeil Pharmaceutical, Raritan, NJ), which contains EE and norgestimate. Twenty-one female subjects with normal menstrual cycles received the oral contraceptive on Days 1 to 21 during two consecutive contraceptive cycles. Subjects received double-blind 40 mg/day laropiprant or placebo on Days 1 to 21 of each contraceptive cycle. Plasma samples were collected predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on Day 21 to measure area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24hr) and maximum concentration observed in plasma (Cmax) of EE and NGMN. Comparability would be declared if the 90% confidence intervals for the geometric mean ratio of AUC0-24hr and Cmax in the absence and presence of laropiprant were within predefined bounds (0.80-1.25). The estimated geom...Continue Reading

References

Sep 1, 1977·Journal of Toxicology and Environmental Health·R E Ranney
Jun 1, 1990·Clinical Pharmacokinetics·D J Back, M L Orme
Sep 1, 1985·Clinical Pharmacology and Therapeutics·J K WilkinW C Streeter
Apr 4, 1981·Lancet·W S Phillips, S L Lightman
Jun 16, 1999·American Journal of Obstetrics and Gynecology·K Sherif
Dec 21, 2000·Current Atherosclerosis Reports·V S Kamanna, M L Kashyap
Dec 21, 2000·Current Atherosclerosis Reports·D M CapuzziC M Intenzo
Aug 17, 2001·Obstetrics and Gynecology·J HilbertH Friedman
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
May 29, 2003·BMC Pediatrics·Jonas F Ludvigsson
Feb 1, 1955·Archives of Biochemistry and Biophysics·R ALTSCHULJ D STEPHEN
Nov 15, 2003·BMC Clinical Pharmacology·Edward MillsDavid Juurlink
Apr 30, 2004·Clinical Pharmacology and Therapeutics·Craig W HendrixCarol Braun Trapnell
Jul 16, 2005·Journal of Internal Medicine·L A Carlson
Apr 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kang ChengM Gerard Waters
Jun 13, 2006·Trends in Pharmacological Sciences·Stefan Offermanns
Sep 30, 2006·Molecular Pharmacology·Zoltán BenyóStefan Offermanns
Sep 30, 2006·The Journal of Investigative Dermatology·Dominique Maciejewski-LenoirDaniel T Connolly
Nov 11, 2006·Bioorganic & Medicinal Chemistry Letters·Deborah A Nicoll-GriffithRobert N Young
Nov 30, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Brian J DeanBindhu Karanam
Mar 30, 2007·Clinical Pharmacology and Therapeutics·E LaiK Gottesdiener
Apr 14, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bindhu KaranamEseng Lai
May 25, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·S W ChangB V Karanam
Mar 1, 2008·The American Journal of Cardiology·John F PaoliniChristie M Ballantyne

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.